GT Biopharma, Inc. Announces Additional Positive Data From Its Phase 1 Clinical Trial For Myasthenia Gravis and Potential for Acceleration of the Start of Its Phase 2 Trial

Print More

WASHINGTON, March 26, 2018 /PRNewswire/ -- GT Biopharma Inc. (OTCQB "GTBP" and Euronext Paris "GTBP.PA") today announced that it has completed the analysis of pharmacokinetic data from its Phase 1

Comments are closed.